Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography

被引:17
作者
Estève, J
Séradour, B
Jacquemier, J
Remontet, L
机构
[1] Hop Enfants La Timone, ARCADES, F-13385 Marseille 5, France
[2] Ctr Hosp Lyon Sud, Serv Biostat, F-69495 Pierre Benite, France
[3] Inst J Paoli I Calmettes, Unite Anat & Cytol Pathol, F-13009 Marseille, France
关键词
D O I
10.1136/jms.9.2.70
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To compare the prognostic factor of breast cancer survival between breast cancer diagnosed in subjects receiving hormone replacement therapy (HRT) before diagnosis to those without such a therapy. Subjects and methods: All breast cancers diagnosed between 1993 and 2000 within the breast cancer screening programme in Bouches do Rhone (France) were analysed for size, node status, and grade according to use, or not, of HRT. Univariate and multivariate analyses were carried out taking into account age, density of the breast, and mode of detection. Results: The breast tumours diagnosed among HRT users had a lower grade whatever the mode of detection. The proportion of node positive tumours was identical in the two groups after adjustment for age. The smaller size of the tumours among HRT users is partly explained by the lower grade of these tumours Conclusion: Although tumours occurring in HRT users have a lower chance of being detected by screening, their prognostic factors, especially the grade of the tumour, are better than in non-users. More work is needed to find which part of this advantage is attributable to better surveillance of women treated with HRT.
引用
收藏
页码:70 / 73
页数:4
相关论文
共 21 条
[1]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[2]   Estrogen replacement therapy and breast cancer: Analysis of age of onset and tumor characteristics [J].
Bilimoria, MM ;
Winchester, DJ ;
Sener, SF ;
Motykie, G ;
Sehgal, UL ;
Winchester, DP .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (02) :200-207
[3]  
Bonnier P, 1998, INT J CANCER, V79, P278
[4]   Hormone replacement therapy and high S phase in breast cancer [J].
Cobleigh, MA ;
Norlock, FE ;
Oleske, DM ;
Starr, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (16) :1528-1530
[5]  
Collaborative Group on Hormonal Factors in Breast Cancer, 1997, LANCET, V350, P1484
[6]   Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation [J].
Fowble, B ;
Hanlon, A ;
Freedman, G ;
Patchefsky, A ;
Kessler, H ;
Nicolaou, N ;
Hoffman, J ;
Sigurdson, E ;
Boraas, M ;
Goldstein, L .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1680-1688
[7]   Hormone replacement therapy and risk of breast cancer with a favorable histology - Results of the Iowa Women's Health Study [J].
Gapstur, SM ;
Morrow, M ;
Sellers, TA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (22) :2091-2097
[8]   Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit [J].
Harding, C ;
Knox, WF ;
Faragher, EB ;
Baildam, A ;
Bundred, NJ .
BRITISH MEDICAL JOURNAL, 1996, 312 (7047) :1646-1647
[9]   Low biologic aggressiveness in breast cancer in women using hormone replacement therapy [J].
Holli, K ;
Isola, J ;
Cuzick, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3115-3120
[10]  
HOSMER DW, 1989, APPL LOGISTIC REGRES, V8, P216